echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The therapeutic activity of HDAC inhibitor Remetinostat gel for basal cell carcinoma

    Clin Cancer Res: The therapeutic activity of HDAC inhibitor Remetinostat gel for basal cell carcinoma

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Basal cell carcinoma (BCC) is a common cancer in the world.
    It is also known as aggressive ulcer

    .
    Basal cell carcinoma is more common in the elderly, and it is more common in the head, face, neck and back of the hands, especially the prominent parts of the face

    .
    It is closely related to sunlight

    .

    In the past, researchers used molecular data of human basal cell carcinoma to screen for drug location and determined that histone deacetylase (HDAC) inhibitors are a potential treatment for basal cell carcinoma
    .
    This study aims to explore the activity of an HDAC inhibitor, Remetinostat, in the treatment of base cell carcinoma

    .

    This is an open-label, single-center Phase II trial that recruits patients with basal cell carcinoma
    .
    All subjects were treated with 1% Remetinostat gel 3 times a day for 6 weeks; tumor diameters were measured at baseline and 8 weeks

    .
    At the end of the study, the residual tumor was surgically removed and observed under a microscope

    .

    Change in tumor diameter at the 8th week

    Change in tumor diameter at the 8th week

    33 tumors from 25 patients were included in the analysis
    .
    Remission definition: The maximum tumor diameter at week 8 was reduced by more than 30% from baseline, and the
    overall response rate was 69.
    7%
    (90 CI 54-82.
    5%)

    .
    Pathological examination showed that
    54.
    8% of tumors completely resolved

    .

    The overall response rate was 69.
    7% The
    overall response rate was 69.
    7%
    54.
    8% The tumor completely resolved
    54.
    8% The tumor completely resolved

    Pathological changes before and after treatment

    Pathological changes before and after treatment

    Pharmacodynamic analysis showed that the level of acetylated histone H3 in the skin tissues before and after treatment was similar, but the phosphorylation level was increased
    .
    No systemic adverse events were reported

    .

    All in all, the HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce the disease burden of basal cell carcinoma
    .
    This study provides human verification for the use of HDAC inhibitors for the treatment of base cell carcinoma

    .

    The HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce the disease burden of basal cell carcinoma.
    The
    HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce basal cells.
    Burden of cancer

    Original source:

    Original source:

    James M.
    Kilgour, et al.
    Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma .
    Clin Cancer Res September 1 2021 27 (17) 4717-4725; DOI :10.
    1158/1078-0432.
    CCR-21-0560

    Phase II Open-Label, Single- Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.